About coramaze

Moderate to severe mitral regurgitation is one of the most frequent structural heart valve diseases. Its prevalence increases with age at 2-3% in adult population, millions of patients are at risk in the US and EU.

For decades, open-heart surgery has been the only available treatment for this disease. Normally, the mitral valve closes when the left ventricle contracts, preventing blood from flowing backwards into the left atrium. MR occurs when the valve fails to seal. Patients with MR suffer from severe symptoms, including difficulty breathing, heart failure, and even increased mortality. Until recently up to 40% of patients with severe MR were excluded from treatment due to advanced age or comorbidities. Furthermore, there is still no therapeutic treatment option for asymptomatic patients with severe MR. In total, the target market volume in key Western markets is approx. € 2 bn p.a. (EU, USA, Japan).

Promising Solution: mitramaze® valve repair system – Technological background


To address this high medical need, coramaze technologies focuses on developing its mitramaze® valve repair system to allow for a minimally invasive transcatheter implantation into the beating heart.

The mitramaze® valve repair system is being developed with the following design features:

  • A low profile delivery catheter system for a transfemoral arterial access route for positioning and implant deployment
  • Atraumatic anchoring within the left atrium
  • A fillable balloon spacer for an optimal coaptation of valve leaflets without injury to adjacent tissue structure.
  • Implant retrievable and repositionable prior to full deployment.

Promising pre-clinical animal data support the development from a design concept into a clinical prototype for a first-in-human clinical trial expected to enroll in 2020.


Press releases

1. September 2015

coramaze technologies raises EUR 4.5 million to advance novel transfemoral mitral valve repair system into the clinic

mitramaze® – First transfemoral mitral valve repair system with atraumatic anchoring being developed coramaze technologies GmbH, a German medical device company, is developing the mitramaze® valve repair system – a novel concept for transcatheter mitral valve repair (TMVRep) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR). coramaze announced today the closing of a EUR 4.5 million (US$ 5.15 million) series A financing round led by
12. February 2014

coramaze technologies GmbH receives € 1 million to develop an innovative medical device for the minimally invasive treatment of heart valve diseases

coramaze technologies GmbH, a German company founded and based in Essen as a spin-off from the Western German Heart Center, is developing an innovative medical device for the minimally invasive treatment of one of the most common structural heart valve diseases, mitral regurgitation. The mitramaze® valve repair system technology has been developed through a technological research project funded by the EXIST research transfer of the German Federal Ministry of Economics and Technology. The compan

Info & Contact

Boaz Harari


Mühlenhof 7-9
40721 Hilden

In portfolio

06. Feb 2014

Dr. Anke Caßing

Principal / Authorized Signatory